(HR) Healthcare Realty Trust - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US42226K1051
Stock: Medical Buildings, Outpatient Facilities, Real Estate
Total Rating 43
Risk 64
Buy Signal 0.01
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.72% |
| Yield on Cost 5y | 6.39% |
| Yield CAGR 5y | -18.43% |
| Payout Consistency | 91.9% |
| Payout Ratio | 251.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.6% |
| Relative Tail Risk | -2.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | 1.58 |
| Character TTM | |
|---|---|
| Beta | 0.288 |
| Beta Downside | 0.302 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.21% |
| CAGR/Max DD | 0.02 |
Description: HR Healthcare Realty Trust January 08, 2026
Healthcare Realty Trust (NYSE: HR) is a specialty REIT that acquires, develops, and manages outpatient medical facilities located primarily on or adjacent to leading hospital campuses. As of September 30 2025 the portfolio comprised 579 properties across 28 states, totaling roughly 33.6 million sq ft, and the enterprise value was about $11.1 billion.
Key operating metrics that analysts watch include an occupancy rate that has consistently hovered around 96 % and a funds-from-operations (FFO) growth rate of roughly 5 %-6 % YoY over the past three years. The business benefits from secular demand drivers such as an aging U.S. population and the shift toward outpatient care, while lease terms are typically tied to CPI, making the REIT moderately sensitive to inflation and interest-rate movements.
If you want a data-rich, side-by-side comparison of HR’s valuation and risk profile, ValueRay’s research platform offers a useful starting point.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -367.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: 21.56% < 20% (prev -9.53%; Δ 31.09% < -1%) |
| CFO/TA 0.05 > 3% & CFO 462.8m > Net Income -367.3m |
| Net Debt (4.68b) to EBITDA (489.6m): 9.56 < 3 |
| Current Ratio: 1.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (350.0m) vs 12m ago -2.51% < -2% |
| Gross Margin: 61.79% > 18% (prev 0.49%; Δ 6130 % > 0.5%) |
| Asset Turnover: 11.23% > 50% (prev 11.46%; Δ -0.23% > 0%) |
| Interest Coverage Ratio: -0.70 > 6 (EBITDA TTM 489.6m / Interest Expense TTM 222.1m) |
Altman Z'' 0.13
| A: 0.03 (Total Current Assets 648.1m - Total Current Liabilities 392.6m) / Total Assets 9.86b |
| B: 0.01 (Retained Earnings 113.8m / Total Assets 9.86b) |
| C: -0.01 (EBIT TTM -154.9m / Avg Total Assets 10.55b) |
| D: 0.02 (Book Value of Equity 110.9m / Total Liabilities 5.11b) |
| Altman-Z'' Score: 0.13 = B |
Beneish M -4.00
| DSRI: 0.26 (Receivables 84.1m/353.7m, Revenue 1.18b/1.29b) |
| GMI: 0.79 (GM 61.79% / 48.76%) |
| AQI: 0.95 (AQ_t 0.91 / AQ_t-1 0.96) |
| SGI: 0.92 (Revenue 1.18b / 1.29b) |
| TATA: -0.08 (NI -367.3m - CFO 462.8m) / TA 9.86b) |
| Beneish M-Score: -4.00 (Cap -4..+1) = AAA |
What is the price of HR shares?
As of February 08, 2026, the stock is trading at USD 16.92 with a total of 8,235,601 shares traded.
Over the past week, the price has changed by +0.77%, over one month by -1.51%, over three months by -4.26% and over the past year by +9.27%.
Over the past week, the price has changed by +0.77%, over one month by -1.51%, over three months by -4.26% and over the past year by +9.27%.
Is HR a buy, sell or hold?
Healthcare Realty Trust has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold HR.
- StrongBuy: 1
- Buy: 0
- Hold: 9
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the HR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.1 | 12.9% |
| Analysts Target Price | 19.1 | 12.9% |
| ValueRay Target Price | 18 | 6.4% |
HR Fundamental Data Overview February 03, 2026
P/E Forward = 10.8342
P/S = 4.879
P/B = 1.2607
P/EG = 4.67
Revenue TTM = 1.18b USD
EBIT TTM = -154.9m USD
EBITDA TTM = 489.6m USD
Long Term Debt = 4.34b USD (from longTermDebt, last quarter)
Short Term Debt = 149.0m USD (from shortTermDebt, last quarter)
Debt = 4.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.68b USD (from netDebt column, last quarter)
Enterprise Value = 10.56b USD (5.88b + Debt 4.72b - CCE 43.3m)
Interest Coverage Ratio = -0.70 (Ebit TTM -154.9m / Interest Expense TTM 222.1m)
EV/FCF = 48.18x (Enterprise Value 10.56b / FCF TTM 219.2m)
FCF Yield = 2.08% (FCF TTM 219.2m / Enterprise Value 10.56b)
FCF Margin = 18.50% (FCF TTM 219.2m / Revenue TTM 1.18b)
Net Margin = -31.00% (Net Income TTM -367.3m / Revenue TTM 1.18b)
Gross Margin = 61.79% ((Revenue TTM 1.18b - Cost of Revenue TTM 452.8m) / Revenue TTM)
Gross Margin QoQ = 61.90% (prev 63.05%)
Tobins Q-Ratio = 1.07 (Enterprise Value 10.56b / Total Assets 9.86b)
Interest Expense / Debt = 1.15% (Interest Expense 54.2m / Debt 4.72b)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.4m (EBIT -154.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.65 (Total Current Assets 648.1m / Total Current Liabilities 392.6m)
Debt / Equity = 1.01 (Debt 4.72b / totalStockholderEquity, last quarter 4.68b)
Debt / EBITDA = 9.56 (Net Debt 4.68b / EBITDA 489.6m)
Debt / FCF = 21.36 (Net Debt 4.68b / FCF TTM 219.2m)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.48% (Net Income -367.3m / Total Assets 9.86b)
RoE = -7.42% (Net Income TTM -367.3m / Total Stockholder Equity 4.95b)
RoCE = -1.67% (EBIT -154.9m / Capital Employed (Equity 4.95b + L.T.Debt 4.34b))
RoIC = -1.28% (negative operating profit) (NOPAT -122.4m / Invested Capital 9.60b)
WACC = 4.27% (E(5.88b)/V(10.60b) * Re(6.98%) + D(4.72b)/V(10.60b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.91%
[DCF Debug] Terminal Value 87.37% ; FCFF base≈223.5m ; Y1≈249.8m ; Y5≈330.2m
Fair Price DCF = 14.37 (EV 9.73b - Net Debt 4.68b = Equity 5.05b / Shares 351.6m; r=5.90% [WACC]; 5y FCF grow 13.61% → 2.90% )
EPS Correlation: -41.22 | EPS CAGR: -13.06% | SUE: -0.02 | # QB: 0
Revenue Correlation: 59.83 | Revenue CAGR: 23.27% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.09 | Chg30d=+0.040 | Revisions Net=+0 | Growth EPS=+47.1% | Growth Revenue=-1.2%
P/S = 4.879
P/B = 1.2607
P/EG = 4.67
Revenue TTM = 1.18b USD
EBIT TTM = -154.9m USD
EBITDA TTM = 489.6m USD
Long Term Debt = 4.34b USD (from longTermDebt, last quarter)
Short Term Debt = 149.0m USD (from shortTermDebt, last quarter)
Debt = 4.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.68b USD (from netDebt column, last quarter)
Enterprise Value = 10.56b USD (5.88b + Debt 4.72b - CCE 43.3m)
Interest Coverage Ratio = -0.70 (Ebit TTM -154.9m / Interest Expense TTM 222.1m)
EV/FCF = 48.18x (Enterprise Value 10.56b / FCF TTM 219.2m)
FCF Yield = 2.08% (FCF TTM 219.2m / Enterprise Value 10.56b)
FCF Margin = 18.50% (FCF TTM 219.2m / Revenue TTM 1.18b)
Net Margin = -31.00% (Net Income TTM -367.3m / Revenue TTM 1.18b)
Gross Margin = 61.79% ((Revenue TTM 1.18b - Cost of Revenue TTM 452.8m) / Revenue TTM)
Gross Margin QoQ = 61.90% (prev 63.05%)
Tobins Q-Ratio = 1.07 (Enterprise Value 10.56b / Total Assets 9.86b)
Interest Expense / Debt = 1.15% (Interest Expense 54.2m / Debt 4.72b)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.4m (EBIT -154.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.65 (Total Current Assets 648.1m / Total Current Liabilities 392.6m)
Debt / Equity = 1.01 (Debt 4.72b / totalStockholderEquity, last quarter 4.68b)
Debt / EBITDA = 9.56 (Net Debt 4.68b / EBITDA 489.6m)
Debt / FCF = 21.36 (Net Debt 4.68b / FCF TTM 219.2m)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.48% (Net Income -367.3m / Total Assets 9.86b)
RoE = -7.42% (Net Income TTM -367.3m / Total Stockholder Equity 4.95b)
RoCE = -1.67% (EBIT -154.9m / Capital Employed (Equity 4.95b + L.T.Debt 4.34b))
RoIC = -1.28% (negative operating profit) (NOPAT -122.4m / Invested Capital 9.60b)
WACC = 4.27% (E(5.88b)/V(10.60b) * Re(6.98%) + D(4.72b)/V(10.60b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.91%
[DCF Debug] Terminal Value 87.37% ; FCFF base≈223.5m ; Y1≈249.8m ; Y5≈330.2m
Fair Price DCF = 14.37 (EV 9.73b - Net Debt 4.68b = Equity 5.05b / Shares 351.6m; r=5.90% [WACC]; 5y FCF grow 13.61% → 2.90% )
EPS Correlation: -41.22 | EPS CAGR: -13.06% | SUE: -0.02 | # QB: 0
Revenue Correlation: 59.83 | Revenue CAGR: 23.27% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.09 | Chg30d=+0.040 | Revisions Net=+0 | Growth EPS=+47.1% | Growth Revenue=-1.2%